Van de Vijver Pieter, Vondenhoff Gaston H M, Kazakov Teymur S, Semenova Ekaterina, Kuznedelov Konstantin, Metlitskaya Anastasia, Van Aerschot Arthur, Severinov Konstantin
Waksman Institute, 190 Frelinghuysen Road, Piscataway, NJ 08854, USA.
J Bacteriol. 2009 Oct;191(20):6273-80. doi: 10.1128/JB.00829-09. Epub 2009 Aug 14.
Microcin C (McC) is a potent antibacterial agent produced by some strains of Escherichia coli. McC consists of a ribosomally synthesized heptapeptide with a modified AMP attached through a phosphoramidate linkage to the alpha-carboxyl group of the terminal aspartate. McC is a Trojan horse inhibitor: it is actively taken inside sensitive cells and processed there, and the product of processing, a nonhydrolyzable aspartyl-adenylate, inhibits translation by preventing aminoacylation of tRNA(Asp) by aspartyl-tRNA synthetase (AspRS). Changing the last residue of the McC peptide should result in antibacterial compounds with targets other than AspRS. However, mutations that introduce amino acid substitutions in the last position of the McC peptide abolish McC production. Here, we report total chemical synthesis of three McC-like compounds containing a terminal aspartate, glutamate, or leucine attached to adenosine through a nonhydrolyzable sulfamoyl bond. We show that all three compounds function in a manner similar to that of McC, but the first compound inhibits bacterial growth by targeting AspRS while the latter two inhibit, respectively, GluRS and LeuRS. Our approach opens a way for creation of new antibacterial Trojan horse agents that target any 1 of the 20 tRNA synthetases in the cell.
微菌素C(McC)是由某些大肠杆菌菌株产生的一种强效抗菌剂。McC由核糖体合成的七肽组成,该七肽通过磷酰胺键与末端天冬氨酸的α-羧基连接有一个修饰的AMP。McC是一种特洛伊木马抑制剂:它被主动摄取到敏感细胞内并在那里进行加工,加工产物即一种不可水解的天冬氨酰腺苷酸,通过阻止天冬氨酰-tRNA合成酶(AspRS)对tRNA(Asp)进行氨酰化来抑制翻译。改变McC肽的最后一个残基应该会产生以AspRS以外的其他物质为靶点的抗菌化合物。然而,在McC肽的最后一个位置引入氨基酸取代的突变会消除McC的产生。在此,我们报道了三种类McC化合物的全化学合成,这些化合物含有通过不可水解的氨磺酰键与腺苷相连的末端天冬氨酸、谷氨酸或亮氨酸。我们表明,这三种化合物的作用方式与McC相似,但第一种化合物通过靶向AspRS来抑制细菌生长,而后两种化合物分别抑制谷氨酰胺-tRNA合成酶(GluRS)和亮氨酰-tRNA合成酶(LeuRS)。我们的方法为创造针对细胞中20种tRNA合成酶中任何一种的新型抗菌特洛伊木马剂开辟了道路。